FIGURE 1.

Schematic illustration of the fabrication of JMs and their utilization for tumor treatment. (A) Preparation of JM_ICG/DOX incorporating TCO‐DOX and Tz‐ICG through microfluidic electrospray techniques. (B) The therapeutic mechanism of JM_ICG/DOX involves the gradual release of TCO‐DOX and Tz‐ICG at the tumor resection site post‐injection. This release initiates a bioorthogonal reaction that subsequently activates the chemotherapeutic effects. Additionally, the JMs exhibit significant photothermal therapy (PTT) effects when exposed to 808 nm light irradiation, attributed to the intrinsic photothermal properties of Tz‐ICG. As a result, the JM_ICG/DOX demonstrated efficacy in eradicating residual cancer cells, thereby inhibiting both local tumor proliferation and distant metastasis through the integrated application of bioorthogonal chemotherapy and PTT.